According to FutureWise analysis the market for Erythropoietin in 2023 is US$ 15.56 billion, and is expected to reach US$ 37.49 billion by 2031 at a CAGR of 11.62%.
Erythropoietin, also known as erythropoetin, haematopoietin, or haemopoietin, is a glycoprotein cytokine that increases red blood cell synthesis (erythropoiesis) in the bone marrow in response to cellular hypoxia. EPO is released in adequate quantities to compensate for normal red blood cell turnover at low levels (about 10 mU/mL). Any anaemia, as well as hypoxemia due to chronic lung disease, are common causes of cellular hypoxia resulting in increased EPO levels (up to 10 000 mU/mL). Interstitial fibroblasts in the kidney produce erythropoietin in close proximity to the peritubular capillary and proximal convoluted tubule. The liver's perisinusoidal cells produce it as well. In the foetal and neonatal era, liver production predominates; in adulthood, renal production predominates. It is related to thrombopoietin. Exogenous erythropoietin, also known as recombinant human erythropoietin (rhEPO), is manufactured in cell culture using recombinant DNA technology. Erythropoiesis-stimulating drugs (ESA) include epoetin alfa and epoetin beta. ESAs are used to treat anaemia caused by chronic renal disease, myelodysplasia, and cancer chemotherapy-induced anaemia. Death, myocardial infarction, stroke, venous thromboembolism, and tumour recurrence are all possible side effects of treatment. When EPO medication boosts haemoglobin levels above 11 g/dL to 12 g/dL, the risk increases: this should be avoided. rhEPO has been utilised as a performance-enhancing substance in the past.
FutureWise Market Research has instantiated a report that provides an intricate analysis of Erythropoietin Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.
According to the research study conducted by FutureWise research analysts, the Erythropoietin Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.